registry, as of 2025-11-28Stale
https://clinicaltrials.gov/study/NCT05814107
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Australia First Pty Ltd. Enrollment 94. Conditions Type 2 Diabetes; Overweight or Obesity. This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
ClinicalTrials.gov NCT05814107 protocol and results modules
Registry NCT05814107
Phase Phase 1
Status Completed
Enrollment 94
Start 2023-05-09
Primary completion 2025-11-07
Study completion 2025-11-07
Catalyst Primary completion. 2025-11-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale
Part 1: CT-996 SAD Cohort 1
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 1: CT-996 SAD Cohort 2
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 1: CT-996 SAD Cohort 4
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 1: CT-996 SAD Cohort 6
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 1: Placebo SAD Cohort
Population Type 2 Diabetes; Overweight or Obesity
Part 2: CT-996 MAD Cohort 1
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 2: CT-996 MAD Cohort 2
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 2: CT-996 MAD Cohort 3
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 2: Placebo MAD Cohort
Population Type 2 Diabetes; Overweight or Obesity
Part 3: CT-996 MD T2DM Cohort 1
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 3: CT-996 MD T2DM Cohort 2
Comparator placebo
Population Type 2 Diabetes; Overweight or Obesity
Part 3: Placebo MD T2DM Cohort
Population Type 2 Diabetes; Overweight or Obesity